Endo Pharmaceuticals Holdings (ENDP) Tops Q3 EPS by 2c; Adjusts FY12 Outlook
Tweet
Share
E-mailGet Alerts ENDP Hot Sheet
Price: $0.29 --0%
Financial Fact:
LOSS ON EXTINGUISHMENT OF DEBT, NET: 0
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
LOSS ON EXTINGUISHMENT OF DEBT, NET: 0
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Endo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q3 EPS of $1.28, $0.02 better than the analyst estimate of $1.26. Revenue for the quarter came in at $750 million versus the consensus estimate of $788.53 million.
Sees FY2012 EPS of $5.00-$5.10, versus the consensus of $5.03. Endo Pharmaceuticals Holdings sees FY2012 revenue of $3.05 billion, versus the consensus of $3.10 billion.
For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.
Sees FY2012 EPS of $5.00-$5.10, versus the consensus of $5.03. Endo Pharmaceuticals Holdings sees FY2012 revenue of $3.05 billion, versus the consensus of $3.10 billion.
For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Is Treasury selloff a major issue for stock market bulls?
- The LGL Group (LGL) Misses Q2 EPS by 8c
- DA Davidson Reiterates Buy Rating on Walmart (WMT) Ahead of Earnings
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
